Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
Prophylaxis is the global standard of care for haemophilia A (HA), and its adoption has been accelerated by wide use of emicizumab prophylaxis globally. Reports on the prophylaxis in people with haemophilia living in Africa are limited.
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-03-01
|
| Series: | The Journal of Haemophilia Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/jhp-2025-0005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331010577104896 |
|---|---|
| author | Mwakichako Rebbecca Wughanga Mnkugwe Rajabu Hussein Chamba Clara Kunambi Peter Bruckman Martha Schuh Anna Munroe Michelle Kaaya Gladys Ally Mwashungi Nasser Ahlam Mawala William Lyimo Magdalena Mahlangu Johnny Rwezaula Stella |
| author_facet | Mwakichako Rebbecca Wughanga Mnkugwe Rajabu Hussein Chamba Clara Kunambi Peter Bruckman Martha Schuh Anna Munroe Michelle Kaaya Gladys Ally Mwashungi Nasser Ahlam Mawala William Lyimo Magdalena Mahlangu Johnny Rwezaula Stella |
| author_sort | Mwakichako Rebbecca Wughanga |
| collection | DOAJ |
| description | Prophylaxis is the global standard of care for haemophilia A (HA), and its adoption has been accelerated by wide use of emicizumab prophylaxis globally. Reports on the prophylaxis in people with haemophilia living in Africa are limited. |
| format | Article |
| id | doaj-art-3c838d6b3b5b4db8a133b176b48e8fcd |
| institution | Kabale University |
| issn | 2055-3390 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | The Journal of Haemophilia Practice |
| spelling | doaj-art-3c838d6b3b5b4db8a133b176b48e8fcd2025-08-20T03:46:45ZengSciendoThe Journal of Haemophilia Practice2055-33902025-03-01121152210.2478/jhp-2025-0005Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experienceMwakichako Rebbecca Wughanga0Mnkugwe Rajabu Hussein1Chamba Clara2Kunambi Peter3Bruckman Martha4Schuh Anna5Munroe Michelle6Kaaya Gladys7Ally Mwashungi8Nasser Ahlam9Mawala William10Lyimo Magdalena11Mahlangu Johnny12Rwezaula Stella13Muhimbili University of Health and Allied Sciences,Dar es Salaam, Tanzania.Muhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaUniversity of the Witwatersrand Johannesburg,Johannesburg, South AfricaMuhimbili University of Health and Allied Sciences,Dar es Salaam, TanzaniaProphylaxis is the global standard of care for haemophilia A (HA), and its adoption has been accelerated by wide use of emicizumab prophylaxis globally. Reports on the prophylaxis in people with haemophilia living in Africa are limited.https://doi.org/10.2478/jhp-2025-0005emicizumabhaemophilia ableedingadherenceprophylaxisafricareal-world experience |
| spellingShingle | Mwakichako Rebbecca Wughanga Mnkugwe Rajabu Hussein Chamba Clara Kunambi Peter Bruckman Martha Schuh Anna Munroe Michelle Kaaya Gladys Ally Mwashungi Nasser Ahlam Mawala William Lyimo Magdalena Mahlangu Johnny Rwezaula Stella Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience The Journal of Haemophilia Practice emicizumab haemophilia a bleeding adherence prophylaxis africa real-world experience |
| title | Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience |
| title_full | Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience |
| title_fullStr | Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience |
| title_full_unstemmed | Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience |
| title_short | Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience |
| title_sort | outcomes challenges and prospects of emicizumab prophylaxis in sub saharan africa insights from the tanzanian experience |
| topic | emicizumab haemophilia a bleeding adherence prophylaxis africa real-world experience |
| url | https://doi.org/10.2478/jhp-2025-0005 |
| work_keys_str_mv | AT mwakichakorebbeccawughanga outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT mnkugwerajabuhussein outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT chambaclara outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT kunambipeter outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT bruckmanmartha outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT schuhanna outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT munroemichelle outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT kaayagladys outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT allymwashungi outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT nasserahlam outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT mawalawilliam outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT lyimomagdalena outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT mahlangujohnny outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience AT rwezaulastella outcomeschallengesandprospectsofemicizumabprophylaxisinsubsaharanafricainsightsfromthetanzanianexperience |